Lipistad

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lipistad

Lipistad is a prescription-only, synthetic pharmaceutical whose core active ingredient is Atorvastatin, typically administered as its calcium salt. It is classified within the definitive pharmacological group of HMG-CoA Reductase Inhibitors, commonly known as statins or hypolipidemic agents. This classification establishes the drug as a foundational medication used for the therapeutic modification of adverse plasma lipid profiles.

Property Description
Active ingredient Atorvastatin
Form Film-coated tablet
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
General use Management of high blood fat levels
Origin Synthetic

What Type of Medicine is Lipistad? (Identity and Classification)

Lipistad is a core treatment type distinguished by its effective mechanism for managing high levels of fats in the blood. Statins are a highly effective class for lowering low-density lipoprotein cholesterol (LDL-C). As a statin, Lipistad is primarily positioned for the widespread management of hyperlipidaemia in adult patients.


Composition and Form: What is Atorvastatin and How is Lipistad Taken?

Lipistad’s essential component is the active ingredient Atorvastatin. This substance is a complex synthetic compound with a specific chemical structure. Lipistad is characterized as a single active ingredient product, formulated exclusively as a film-coated tablet for oral administration. The film-coated design ensures convenient patient intake and effective systemic delivery of the synthetic compound. The use of a single active ingredient allows for focused therapy targeting the specific metabolic pathways influenced by Atorvastatin.


What is the General Purpose of This Statin Medication?

The general purpose of Lipistad is the systemic management of high blood fat levels, specifically targeting the reduction of cholesterol and triglycerides. The medicine works by acting as an inhibitor to the enzyme responsible for the rate-limiting step in the liver's natural production of cholesterol. By blocking cholesterol production, Lipistad helps lower harmful LDL-C and triglycerides (TG) circulating in the bloodstream. This action is clinically recognized as critical for supporting long-term cardiovascular health maintenance, aligning with the drug's overall goal as a powerful lipid-lowering agent.

Regulatory References

  1. HMG-CoA Reductase Inhibitors (Statins) - NIH StatPearls

What side effects are possible with Lipistad?

Possible Side Effects and Safety Information

The official safety documentation for Lipistad (Atorvastatin) structures possible side effects by frequency and the body system affected, ensuring a clear communication of the risk profile as defined by regulatory authorities.

Commonly Documented Adverse Reactions

Adverse reactions classified as Very Common (ge 1/10) include nasopharyngitis. Common effects (occurring in ge 1/100 to < 1/10 patients) typically involve the Nervous System (headache), Gastrointestinal System (nausea, diarrhea, flatulence, dyspepsia), and Musculoskeletal System (myalgia, arthralgia, pain in extremity). Other common effects include hyperglycaemia and elevations in blood creatine kinase, which requires monitoring.

Serious Safety Concerns

The regulatory profile highlights rare but critical adverse reactions. Rhabdomyolysis, a severe form of muscle breakdown that may lead to acute renal failure, is a key safety concern in the Musculoskeletal domain. Additionally, rare reports of Hepatic Failure (fatal and non-fatal) and severe allergic reactions such as Anaphylaxis and Angioneurotic Oedema are officially documented.

Safety Restrictions and Special Populations

Lipistad is contraindicated in patients with active liver disease or persistent, unexplained elevations of liver enzymes above defined limits. It is also strictly contraindicated during pregnancy and lactation due to the potential for fetal harm. Safety notes indicate that the risk of myopathy is heightened in patients with predisposing factors, including older age (ge 65 years) and pre-existing renal or hepatic impairment. Interstitial lung disease has been reported in exceptional cases, primarily associated with long-term therapy.

Overdose and Emergency Response

Overdose Scope

Feature Official Regulatory Statements
Documented overdose presentations No specific symptoms are consistently reported in official documentation regarding acute, massive overdose. Overdose signs are generally expected to align with the drug’s known adverse effect profile.
Physiological systems affected (as stated in label) The primary risks are related to skeletal muscle effects (rhabdomyolysis) and potential resulting acute renal failure due to myoglobinuria.
Population-specific overdose notes (if applicable) The presence of renal impairment is a documented risk factor for myopathy and rhabdomyolysis, necessitating close observation during management.
When immediate medical help is required (label-derived phrasing only) Any suspected or known overdose requires the user to seek immediate medical attention and contact emergency services or a Poison Control Center immediately.

Overdose Classifications

Feature Official Regulatory Statements
Severity classification (as defined in official documents) The primary concern is the potential for severe outcomes, specifically rhabdomyolysis and associated renal injury.
Regulatory basis Information is derived from the Summary of Product Characteristics (SmPC) and U.S. Prescribing Information (FDA).

Official Overdose Statements

  • Overdose management must be symptomatic and supportive because no specific antidote is known for Atorvastatin.
  • Management procedures include close monitoring of laboratory parameters, notably Creatine Kinase (CK) levels and liver function tests.
  • Due to the drug's extensive binding to plasma proteins, regulatory documents state that haemodialysis is not expected to significantly enhance clearance.

Connection to the Overall Overdose Profile

The regulatory profile for Lipistad overdose defines management around immediate emergency action and specialized supportive care, rather than specific reversal. The focus is on urgently monitoring for and treating the most serious documented complication, which is the progression to muscle breakdown and subsequent kidney impairment, exactly as described in official government labeling.

Therapeutic Uses of Lipistad

Easing Sudden or Intensifying Symptom Patterns

Lipistad is commonly used in contexts involving certain distressing symptoms and conditions characterized by periods of heightened symptoms. The medicine is applicable within clinical settings that involve acute or disruptive symptom patterns, and is used in areas where short-term symptom management is appropriate. It helps address symptom clusters that may become intense or disruptive, providing support that helps ease the overall symptom burden.


Applied During Phases of Increased Distress or Discomfort

The medication is relevant in contexts marked by increased discomfort or tension, often used during phases when symptoms become more noticeable. It may assist with managing symptoms that create noticeable functional strain, and it contributes to improved comfort during periods of heightened symptoms. It is applied across domains where additional symptomatic support is needed.

“It is relevant when supportive symptom management is appropriate.”


Supportive Management for Episodic or Fluctuating Manifestations

Lipistad is used across conditions presenting with acute episodes and is applicable when symptoms create noticeable physiological strain. The medication is applied in scenarios where additional management of discomfort is required, especially in conditions involving episodic or fluctuating manifestations. It is relevant when supportive symptom management is appropriate, playing a role in managing symptoms that interfere with daily comfort.

Quick Fact: Relief for Symptoms That Interfere with Daily Functioning

Eligibility and Restrictions for Use

Lipistad (Atorvastatin) eligibility is defined by official regulatory criteria concerning hepatic function, reproductive status, and age.

Populations for Whom Use is Contraindicated

Contraindication Entity
Active Liver Disease (including unexplained persistent elevations of serum transaminases 3x ULN)
Pregnancy or women who may become pregnant (must use adequate contraception)
Lactation (Breastfeeding)
Known Hypersensitivity to the active substance or excipients
Concomitant use with Glecaprevir/Pibrentasvir (Hepatitis C antivirals)

Age-Related Eligibility and Use Restrictions

Age Group or Condition Regulatory Status
Adults Generally permitted for use [Source 2.4]
Children and Adolescents Indicated for those aged 10 years and older with specific familial hypercholesterolaemia [Source 2.2]
Children below 10 years Use is not indicated [Source 2.2]
Geriatric Patients (65 years) Eligible, but advanced age is listed as a predisposing factor for myopathy/rhabdomyolysis [Source 2.4]

Conditional Use Based on Other Factors

Use requires caution in patients with a history of liver disease or those who consume substantial quantities of alcohol [Source 2.2]. Renal impairment does not require a dose change but is noted as a risk factor for muscle disorders [Source 2.4]. This regulatory framework strictly dictates who may and may not be considered for treatment, based only on clinical status and official label constraints.

What should I know about interactions with other medicines?

Lipistad Interactions with other medicines and products

Lipistad (Atorvastatin) interactions are officially documented by regulatory authorities, primarily focusing on pharmacokinetic and pharmacodynamic mechanisms that modify drug exposure or increase specific adverse risks.


Contraindicated and Restricted Combinations

Co-administration with Cyclosporine and certain combinations of HIV/HCV protease inhibitors (e.g., Tipranavir plus Ritonavir) is strictly contraindicated due to the risk of significant increases in Atorvastatin plasma concentrations and muscle toxicity. Strong CYP3A4 inhibitors, such as Clarithromycin and Itraconazole, increase Atorvastatin exposure, which requires formal dose limitations on Atorvastatin when co-administered.


Pharmacokinetic and Pharmacodynamic Effects

Interactions are documented based on the inhibition or induction of the CYP3A4 enzyme and interference with the OATP1B1 uptake transport protein. Substances like Rifampin are classified as CYP3A4 inducers that reduce Atorvastatin plasma levels, necessitating a mandatory timing rule where both medicines must be simultaneously co-administered. Conversely, Oral Contraceptives (Ethinyl Estradiol and Norethindrone) may have their plasma levels increased by co-administration with Atorvastatin. Pharmacodynamic interactions are observed with Fibric Acid Derivatives and lipid-modifying doses of Niacin (≥1 g/day), which result in an additive risk of serious skeletal muscle effects (myopathy).


Food and Population Considerations

The consumption of large quantities of Grapefruit Juice (over 1.2 liters daily) is officially restricted due to its documented effect of increasing Atorvastatin plasma concentrations. Interaction risk is also documented as heightened in patients with hepatic impairment, as systemic exposure to Atorvastatin is markedly increased in this population.

Mechanism of Action

How Lipistad Works

Lipistad's mechanism is defined by a dual action: selective enzymatic inhibition in the liver and subsequent modulation of vascular cell function. The active ingredient, Atorvastatin, functions as a competitive inhibitor of the enzyme HMG-CoA Reductase within the liver, blocking the rate-limiting step of the Mevalonate Pathway.

This inhibition reduces the de novo synthesis of cholesterol, creating an intracellular deficit that triggers the upregulation of Hepatic LDL Receptors. The resulting higher density of these receptors promotes the extraction of LDL-C and VLDL directly from the circulating blood plasma.

Beyond lipid modulation, the pathway block also reduces crucial isoprenoid intermediates. This consequence impairs the activation of small signaling proteins (GTPases) that mediate processes in the vascular endothelium. This mechanism influences the structural integrity of the vessel lining and contributes to the reduction of pro-inflammatory markers.

Dosage and Administration Information

Lipistad is administered through the oral route as a film-coated tablet. The medication is taken once daily as a single dose and may be administered with or without food and at any time of the day. This flexible timing allows for consistent adherence to the daily schedule.

The standard starting dosage for adults is typically 10 mg or 20 mg once daily. A starting dose of 40 mg may be used when a significant reduction in low-density lipoprotein cholesterol is required. The established maintenance dosage range extends up to a maximum recommended dose of 80 mg once daily.

Dosage adjustments, if deemed necessary, are typically made at intervals of four weeks or more after the initiation of therapy or previous titration. This waiting period ensures the full therapeutic effect is established before any dose change.

Specific populations have defined dosing parameters. No dosage adjustment is required for patients with renal impairment. In children and adolescents (10 to 17 years old) being treated for heterozygous familial hypercholesterolemia, the starting dose is 10 mg daily, with the maximum daily dose set at 20 mg. If a dose is missed, standard procedure involves skipping the missed amount and resuming the regular daily schedule.

Recent Clinical Evidence

Research evidence / Overview of studies for Lipistad

Evidence for use in Adults with Established Heart Disease (Secondary Prevention)

Research on Lipistad primarily comes from large-scale Randomized Controlled Trials (RCTs) and systematic reviews that combined the data from these trials. For adults with established heart disease, studies monitored major cardiovascular events like Myocardial Infarction (MI) and Stroke. Trials described patterns where the incidence of death or major cardiovascular events was observed to be lower in the treatment group over short follow-up periods. Post-marketing reviews reported that one trial subgroup (patients with recent stroke or TIA) showed patterns suggesting a higher incidence of hemorrhagic stroke was associated with the highest studied dosage compared to placebo.

Evidence for use in Adults with Risk Factors (Primary Prevention)

For primary prevention in adults with risk factors like hypertension or diabetes, RCTs were evaluated against a placebo. These trials monitored the occurrence of first-time major cardiovascular events. Research showed a reduced rate of major coronary events was observed in the treatment group, with the pattern of difference in event rates appearing more pronounced in participants categorized as having a higher baseline risk profile. The absolute difference in event rates in individuals categorized as very low risk is difficult to quantify due to the low event rates.

Evidence in Special Populations and Research Gaps

Dedicated research was evaluated in pediatric patients (aged 10-17) with Heterozygous Familial Hypercholesterolemia (HeFH). These small, controlled studies explored changes in Lipid Biomarkers (LDL-C) and monitored outcomes related to growth. For these rare conditions, sample sizes were modest, and long-term data concerning outcomes is less extensive than short-term findings. While the research base is extensive, comparative evidence is limited for certain high-risk groups, and data for certain groups remain insufficient, particularly for the very oldest adults. The long-term durability of the patterns observed when beginning use of this medicine is still a subject of ongoing review.

Frequently Asked Questions (FAQ)

Common questions about Lipistad (FAQ)


Q: How quickly can someone typically expect Lipistad to start working?

Studies indicate that the initial lowering of low-density lipoprotein cholesterol (LDL-C), the harmful type of cholesterol, is typically seen within two weeks of beginning treatment. The greatest reduction in cholesterol levels, which is the intended effect, is generally achieved within approximately four weeks after starting or adjusting the dose.


Q: Is it common to feel tired when first starting Lipistad?

Official product information on atorvastatin, the active ingredient in Lipistad, often lists general fatigue or tiredness as a possible side effect. While not all regulatory labels classify this as a 'common' side effect, it is a pattern observed with medications in this class and is a pattern documented in official safety information.


Q: What does the official information say about using Lipistad long-term?

Regulatory documents describe the drug’s long-term safety profile, indicating that continued monitoring of liver function and muscle symptoms may be part of the long-term management. Official reports mention that very rare adverse effects, such as interstitial lung disease, have been associated with long-term therapy.


Q: Is Lipistad meant to be taken indefinitely?

Lipistad is prescribed for conditions, such as high blood fat levels and the prevention of cardiovascular disease, that often require chronic, long-term therapy. The medication is officially indicated as an adjunct to diet and other non-pharmacological treatments for these ongoing conditions.


Q: Is it necessary to make lifestyle changes while taking Lipistad?

Official prescribing information indicates that Lipistad is intended for use as an adjunct to diet. This indicates the medication is considered a supporting component of a comprehensive treatment plan that typically involves diet and other non-pharmacological therapies.


Q: Does Lipistad interact with herbal supplements like St. John's Wort?

Regulatory documents identify St. John's Wort as a strong inducer of the CYP3A4 enzyme. Because Lipistad is metabolized by this enzyme, taking this herbal supplement is documented as resulting in decreased plasma concentrations of the active ingredient.


Q: What if I experience muscle aches after starting Lipistad?

Official regulatory labels note that unexplained muscle pain, tenderness, or weakness should be reported to a healthcare provider. This is particularly important if muscle symptoms are accompanied by symptoms like fever or malaise, as this may indicate a need to monitor for a rare but serious muscle condition called rhabdomyolysis.


Q: Can Lipistad be split or crushed if someone has trouble swallowing pills?

Lipistad is formulated as a film-coated tablet. Standard guidance for film-coated tablets typically suggests that they should not be split, crushed, or chewed unless the tablets are officially scored and specific instructions for manipulation are provided. Altering the tablet form is described as potentially impacting the intended systemic delivery of the medication.


Q: How does Lipistad's description of 'How it works' translate to benefits for a patient?

The drug works by blocking a key enzyme in the liver that makes cholesterol. By doing this, it lowers the levels of harmful LDL-C and is used to reduce the overall risk of major cardiovascular events, such as heart attack and stroke. This action is considered important for supporting long-term cardiovascular health maintenance.


Q: Can Lipistad be taken by people who are sensitive to lactose?

Official information indicates that Lipistad tablets typically contain lactose as an inactive ingredient (excipient). Patients who have been diagnosed with rare hereditary conditions involving galactose intolerance, total lactase deficiency, or certain malabsorption issues are advised to consult with their healthcare provider.


Q: How long does the effect of a Lipistad dose typically last?

The half-life of the active ingredient, atorvastatin, is approximately 14 hours. However, the overall cholesterol-lowering activity of the drug and its active breakdown products (metabolites) persists in the body for up to 20 to 30 hours after a single dose.


Q: Is there a generic version of Lipistad available?

Yes, the active ingredient in Lipistad is Atorvastatin. This substance is widely available from multiple generic manufacturers in various strengths, as the original patent exclusivity for the active compound has expired.


Q: Are there any known interactions between Lipistad and common vitamins?

Regulatory drug interaction documents do not typically list specific interactions with most common vitamins (e.g., Vitamin C or D). However, there is a documented interaction with lipid-modifying doses of Niacin (above 1 gram per day), which increases the additive risk of serious muscle side effects.


Q: Does taking Lipistad require regular blood tests or monitoring?

Official guidelines indicate that monitoring of liver enzyme levels is required before therapy begins and when clinically indicated thereafter. Monitoring of muscle enzyme levels is also required if a patient develops any muscle symptoms during treatment.


Q: Why is Lipistad sometimes prescribed alongside other medications?

Lipistad is approved for use in combination with other lipid-lowering therapies, such as other types of cholesterol medicines. This approach is sometimes necessary when diet alone, or the use of Lipistad as a single agent, is not sufficient to achieve the recommended cholesterol targets.


Q: Are there any specific warnings about driving or operating machinery while on Lipistad?

Official safety documents state that the medication is not generally expected to affect a person's ability to drive or operate machinery. It is noted that patients may need to exercise caution until they determine how the medication affects them, as side effects such as dizziness have been reported.


Q: Can Lipistad affect my mood or mental state?

Post-marketing safety data from regulatory bodies for statin drugs, including atorvastatin, have included rare reports of cognitive impairment. These reports sometimes involve symptoms such as memory loss, confusion, and associated changes in mood or mental state.

How should Lipistad be stored and disposed of?

How to Store and Dispose of Lipistad?

Lipistad (atorvastatin) must be stored under specific environmental controls to maintain its efficacy, as defined by regulatory labeling.


Required Storage Conditions

Lipistad tablets should be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C. The medicine must be kept away from heat, moisture, and direct light, and must not be frozen.


Child Safety and Disposal

For safety, the product must be kept out of the sight and reach of children and remain in its closed original container.

Do not use the medicine after the expiry date. Unused or expired Lipistad must not be discarded in household waste or wastewater. Regulatory instructions require users to return unwanted medicine to a pharmacist for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lipistad found in:

A-Z Index: